MOBILion Systems, based in Chadds Fords, PA, provides high-resolution, high-throughput analysis solutions for the pharmaceutical industry and clinical researchers. Its core product is MOBIE®, the company’s first commercial HighResolution Ion Mobility (HRIM) instrument, launched recently to address characterization challenges in biopharmaceutical drug development and quality monitoring. MOBILion’s technology is positioned to enable earlier disease detection, improve diagnostic accuracy, and accelerate drug development through characterization of more complex biologic therapeutics. The company intends to use the new funding to scale commercialization of MOBIE and to advance product development for expansion into bioprocessing and multiomic biomarker discovery markets. The business is led by Dr. Melissa Sherman. The Series C proceeds will support commercialization and product development efforts. MOBILion Systems has developed SLIM (Structures for Lossless Ion Manipulation), an ion mobility separations platform that separates, identifies and analyzes clinically significant molecules to enable earlier disease detection, improved diagnostic accuracy and enhanced biotherapeutic characterization. The company’s SLIM product delivers high-resolution, high-throughput analysis aimed at pharmaceutical QC and clinical research, accelerating biomarker discovery and improving characterization of protein-based therapeutics. Its first product launched to select beta users in July 2020 via sample analysis collaborations in the company’s applications laboratory and is slated for a full North American launch in 2021. MOBILion intends to use proceeds from its recent funding to build a commercial team to support that launch and to expand development of its product portfolio for pharma QC and diagnostic applications. The technology is already being used for glycan characterization of the SARS‑CoV‑2 spike protein and its interaction with ACE2, supporting research relevant to COVID‑19 therapeutics and vaccine development. The company is led by CEO Melissa Sherman, Ph.D. MOBILion Systems develops and commercializes a patented ion mobility separations platform called Structures for Lossless Ion Manipulation (SLIM) that integrates with mass‑spectrometry workflows to reveal previously undetectable molecules. The company offers SLIM-based products that can enhance or, in some applications, replace liquid chromatography by delivering superior resolution, speed, ease-of-use, and greater instrument uptime. MOBILion is also working on an operator‑simplified, stand‑alone SLIM product for pharmaceutical quality‑control and diagnostic laboratories. The platform is positioned to accelerate biologic drug characterization and biomarker discovery, with claimed throughput of 1000 samples per week and the ability to process population‑scale samples in days rather than years. MOBILion plans to expand its team, advance drug and diagnostic programs with biopharma and academic collaborators, and generate fee‑for‑service revenue through a new applications development laboratory. The company is led by CEO Melissa Sherman, PhD, and is headquartered in Chadds Ford, Pennsylvania.

Total raised

$110M

Funding rounds

3

Latest round

Series C

Latest activity

Jul 2021